SGLT2 inhibitors improved renal impairment accompanied by an increase in blood ketone body levels in HFD-fed Apo E-deficient mice.9 However, this renoprotective effect of SGLT2 inhibitors was abolished in mice lacking the rate-limiting enzyme for endogenous ketone production, HMGCS2.9 Thus, the increase in blood ketone levels contributes to one of the mechanisms of renoprotection by SGLT2 inhibitors in DKD. Here, SLC5A2 is linked to diabetic kidney disease.